<DOC>
	<DOCNO>NCT00403455</DOCNO>
	<brief_summary>Dr. Wang 's merit review aim provide well understanding relationship SLC6A3/SLC6A4 mental health veteran expose high level combat stress , specifically focus PTSD symptom , related co-morbidities , treatment outcome seek new approach therapy Veteran population .</brief_summary>
	<brief_title>Monoamine Transporters Genotypes : Risk PTSD Related Comorbidities</brief_title>
	<detailed_description>Background : Post-traumatic Stress Disorder ( PTSD ) , debilitate condition develop follow exposure trauma , highly prevalent military personnel veteran due high risk trauma exposure combat . Trauma exposure , environmental insult , necessary , sufficient cause PTSD , since everyone exposure trauma develop PTSD . Brain dopamine ( DAT ) serotonin ( 5-HTT ) transporter play critical role regulation stress related psychological behavioral function . Genetic polymorphism affect 5-HTT DAT function , 5 ' promote polymorphism 5-HTT gene ( SLC6A4 ) ( 5-HTTlpr ) 3 ' -untranslated region ( UTR ) -40 bp-variable number tandem repeat ( VNTR ) DAT gene ( SLC6A3 ) , could influence individual susceptibility trauma-related psychopathology . Objective/Hypothesis : The objective application investigate relationship SLC6A3/SLC6A4 mental health veteran expose high level combat stress , specifically focus PTSD symptom , related comorbidities , treatment outcome . The central hypothesis specific genetic variant adversely affect serotonin dopamine neurotransmission constitute risk emergence PTSD relate comorbid symptom trauma exposure ; , variant may influence PTSD related response . Specific Objectives : ( 1 ) To determine specific 5-HTTLPR genotype involvement PTSD symptomatology , ( 2 ) determine influence combine SLC6A3/SLC6A4 genotype PTSD substance dependence , ( 3 ) identify 5 HTTLPR allele affect PTSD symptomatology treatment outcome , ( 4 ) identify additional SLC6A3/SLC6A4 allele associate PTSD related comorbidities . Study Design : We generate preliminary data support hypothesis examine 5-HTTLPR 3'-UTR-VNTR SLC6A3 genotypes 109 combat veteran without PTSD . In proposal , expand finding recruit 300 veteran expose sufficient combat stress define Combat Exposure Scale ( CES ) score &gt; 10 qualify DSM-IV category A PTSD diagnostic criterion , include approximately 150 veteran PTSD veteran PTSD define use DSM-IV diagnostic criterion , Clinician Administered PTSD Scale ( CAPS ) score &gt; 45 150 healthy combat-exposed veteran define CAPS score &lt; 15 . We first apply newly develop extreme discordant phenotype ( EDP ) method examine 5-HTTLPR 3'-UTR-VNTR genotype affect trauma relate psychopathology combat veteran high ( &gt; 45 ) low ( &lt; 15 ) CAPS score . Secondly , single nucleotide polymorphism ( SNPs ) examine across gene assess relatedness PTSD susceptibility resistance . Further analysis relationship polymorphism comorbidities also perform . Thirdly , pharmacogenetic trail ( use sertraline therapeutic agent ) apply assess gene variant influence PTSD treatment outcome . To Safeguard population stratification , genome control method apply genetic analysis .</detailed_description>
	<mesh_term>Paroxetine</mesh_term>
	<criteria>1 . Male female combat veteran age 18 year old meet DSMIIIR criterion principle diagnosis PTSD determine CAPS ; 2 . A minimum 6month duration PTSD illness ; 3 ) CGIS score 4 high total CAPS2 severity score 50 high baseline visit ; 3 . Homozygous either S/S L/L 5HTT ; 4 . Females must pregnant lactating must agree acceptable form contraception receive study medication 1 month . 1 . Presence primary axis I disorder ( concurrent depression permit judged secondary development PTSD ) ; 2 . Suicide ideation attempt within past 3 month ; 3 . Alcohol substance abuse dependence past six month ; 4 . Evidence clinically significant hepatic renal disease ; 5 . Previous seizure disorder condition predisposing seizure , medication might lower seizure threshold 6 . Any acute unstable medical condition might interfere safe conduct study ; 7 . Intolerance hypersensitivity citalopram SSRI ; 8 . Treatment monoamine oxidase inhibitor within 14 day initiate study ; 9 . Concomitant treatment serotonin agonist , SSRIs , meperidine , tramadol medication determine study clinician . 10 . PTSD symptom need immediate treatment determine clinical assessment psychiatrist affiliate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Clinical</keyword>
	<keyword>Genetics</keyword>
	<keyword>Monoamine transporter</keyword>
	<keyword>Pharmacogenetics</keyword>
	<keyword>Post Traumatic Stress Disorder</keyword>
</DOC>